UB Paderborn / Katalog / Suche / in CDI

1 – 14 von 14

Sortiert nach

Molecular biomarker analyses using circulating tumor cells

PloS one, 2010-09, Vol.5 (9), p.e12517-e12517

2010

Link zum Volltext

Verfügbarkeit prüfen

Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up

Blood, 2020-10, Vol.136 (18), p.2027-2037

2020

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non―Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib

Clinical cancer research, 2012-04, Vol.18 (8), p.2391-2401

2012

Link zum Volltext

Verfügbarkeit prüfen

Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma

Blood advances, 2021-06, Vol.5 (12), p.2577-2585

2021

Link zum Volltext

Verfügbarkeit prüfen

A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia

Future oncology (London, England), 2018-09, Vol.14 (22), p.2229-2237

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of FT516, an Off-the-Shelf iPSC-Derived NK Cell Therapy, in Combination with Rituximab in Patients with Relapsed/Refractory B-Cell Lymphoma

Blood, 2021-11, Vol.138 (Supplement 1), p.3873-3873

2021

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma

Blood, 2021-11, Vol.138 (Supplement 1), p.823-823

2021

Link zum Volltext

Verfügbarkeit prüfen

Preliminary results of a phase I trial of FT516, an off-the-shelf natural killer (NK) cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line expressing high-affinity, non-cleavable CD16 (hnCD16), in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.7541-7541

2021

Link zum Volltext

Verfügbarkeit prüfen

Three-year follow-up of treatment-naïve and previously treated patients with Waldenström macroglobulinemia (WM) receiving single-agent zanubrutinib

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.8051-8051

2020

Link zum Volltext

Verfügbarkeit prüfen

Molecular biomarker analyses using circulating tumor cells

Clinical cancer research, 2010-10, Vol.16 (19_Supplement), p.PR3-PR3

2010

Link zum Volltext

Verfügbarkeit prüfen

Abstract 966: Predictive biomarkers of the AKT inhibitor, GDC-0068, in single agent and combination studies

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.966-966

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3153: Detecting PTEN deletions in prostate cancer using circulating tumor cells

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.3153-3153

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5768: Predictive diagnostics from circulating tumor cells

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.5768-5768

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 14 von 14

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(14)
Mit Volltextzugriff
(14)

Publikationsform

Artikel
(14)

Sprache

Englisch
(14)

Erscheinungsjahr

n.n

Thema

Science & Technology
(5)
Humans
(4)
Life Sciences & Biomedicine
(4)
Female
(3)
Male
(3)
Mutation
(3)
Oncology
(3)
Biomarkers
(2)
Biomarkers, Tumor - Genetics
(2)
Clinical Trials And Observations
(2)
Epidermal Growth Factor Receptors
(2)
Hematology
(2)
Lung Neoplasms - Genetics
(2)
Piperidines - Therapeutic Use
(2)
Prognosis
(2)
Pyrazoles - Therapeutic Use
(2)
Pyrimidines - Therapeutic Use
(2)
Tumor Cells
(2)
Tumors
(2)
Waldenstrom Macroglobulinemia - Drug Therapy
(2)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

2 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

2 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Molecular biomarker analyses using circulating tumor cells

Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up

Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non―Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib

Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma

A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia

Phase I Study of FT516, an Off-the-Shelf iPSC-Derived NK Cell Therapy, in Combination with Rituximab in Patients with Relapsed/Refractory B-Cell Lymphoma

Safety and Efficacy of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma

Preliminary results of a phase I trial of FT516, an off-the-shelf natural killer (NK) cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line expressing high-affinity, non-cleavable CD16 (hnCD16), in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL)

Three-year follow-up of treatment-naïve and previously treated patients with Waldenström macroglobulinemia (WM) receiving single-agent zanubrutinib

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Molecular biomarker analyses using circulating tumor cells

Abstract 966: Predictive biomarkers of the AKT inhibitor, GDC-0068, in single agent and combination studies

Abstract 3153: Detecting PTEN deletions in prostate cancer using circulating tumor cells

Abstract 5768: Predictive diagnostics from circulating tumor cells

Suchergebnisse filtern